Skip to main content

Chemomab Therapeutics Ltd.

For the period ended Dec 31, 2025. Filed Mar 23, 2026.

View on SEC.gov

About this filing

The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.

FY2025 · Filed Mar 23, 2026

CMMB$1.32+5.6%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

(Mark One)

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31,2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

Commission File Number 001-40490

Chemomab Therapeutics Ltd.

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

State of Israel

(Jurisdiction of incorporation or organization)

10 Habarzel Street, Building C, 10th Floor, Tel Aviv 6158101, Israel

Telephone+972 77-331-0156

(Address of principal executive offices)

Sigal Fattal

Chief Financial Officer

10 Habarzel Street, Building C, 10th Floor

Tel Aviv, Israel

Telephone+972 77-331-0156

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered, pursuant to Section 12(b) of the Act

Title of each classTrading Symbol(s)Name of each exchange on which registered
American Depositary Shares, each representing eighty (80) ordinary shares, no par value per shareCMMBNasdaq Capital Market
Ordinary shares, no par-value*NANasdaq Capital Market

*Not for trading; only in connection with the registration of American Depository Shares.

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

Indicate the number of outstanding shares of each of the issuer’s classes of capital stock or common stock as of the close of the period covered by the annual report. As of December 31, 2025, the registrant had outstanding 575,381,320 ordinary shares, no par value (equal to 7,192,276 ADSs).

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes☐ No ☒

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes☐ No ☒

Note-Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer☐ Accelerated filer☒ Non-accelerated filer☐ Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

☒ U.S. GAAP☐ International Financial Reporting Standards as issued by the International Accounting Standards Board☐ Other

If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.

Item 17☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes☐ No☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Yes☐ No☒

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS2
PRESENTATION OF FINANCIAL AND OTHER INFORMATION4
PART I5
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS5
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE5
ITEM 3. KEY INFORMATION5
A.[Reserved.]5
B.Capitalization and Indebtedness5
C.Reasons for the Offer and Use of Proceeds5
D.Risk Factors5
ITEM 4. INFORMATION ON THE COMPANY27
A.History and Development of the Company27
B.Business Overview28
C.Organizational Structure
D.Property, Plants and Equipment
ITEM 4A. UNRESOLVED STAFF COMMENTS64
ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS64
A.Operating Results65
B.Liquidity and Capital Resources69
C.Research and Development, Patents and Licenses, Etc.71
D.Trend Information71
E.Critical Accounting Estimates71
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES71
A.Directors and Senior Management71
B.Compensation73
C.Board Practices77
D.Employees86
E.Share Ownership86
F.Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation86
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS86
A.Major Shareholders86
B.Related Party Transactions88
C.Interests of Experts and Counsel88
ITEM 8. FINANCIAL INFORMATION88
A.Consolidated Statements and Other Financial Information88
B.Significant Changes89
ITEM 9. THE OFFER AND LISTING89
A.Offer and Listing Details89
B.Plan of Distribution89
C.Markets89
D.Selling Shareholders89
E.Dilution89
F.Expenses of the Issue89
ITEM 10. ADDITIONAL INFORMATION89
A.Share Capital89
B.Memorandum and Articles of Association89
C.Material Contracts90
D.Exchange Controls90
E.Taxation98
F.Dividends and Paying Agents98
G.Statement by Experts98
H.Documents on Display98
I.Subsidiary Information99
ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK99
ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES99
PART II105
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES105
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS105
ITEM 15. CONTROLS AND PROCEDURES105
ITEM 16. [RESERVED]106
ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT106
ITEM 16B. CODE OF ETHICS106
ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES107
ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES107
ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS107
ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT107
ITEM 16G. CORPORATE GOVERNANCE107
ITEM 16H. MINE SAFETY DISCLOSURE108
ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS108
ITEM 16J. INSIDER TRADING POLICY109
ITEM 16K. CYBERSECURITY109
PART III110
ITEM 17. FINANCIAL STATEMENTS110
ITEM 18. FINANCIAL STATEMENTS110
ITEM 19. EXHIBITS110
SIGNATURES112
INDEXF-1

INTRODUCTION

In this Annual Report on Form 20-F (the “Annual Report”), unless context otherwise requires:

•references to “Chemomab Therapeutics Ltd.”, “Chemomab,” the “Company,” “us,” “we” and “our” refer to Chemomab Therapeutics Ltd., an Israeli company and its consolidated subsidiaries; however, with respect to the presentation of financial results for historical periods that preceded the Merger (as defined below), these terms refer to the financial results of the Company’s wholly owned subsidiary, Chemomab Ltd., which was the accounting acquirer in the Merger;
•references to “ordinary shares,” “our shares” and similar expressions refer to the Company’s ordinary shares, no nominal (par) value;
•references to “ADS” refer to the American Depositary Shares listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CMMB,” each representing eighty (80) ordinary shares;
•references to “dollars,” “U.S. dollars” and “$” are to United States Dollars;
•references to “NIS” are to New Israeli Shekels;
•references to the “Companies Law” are to Israel’s Companies Law, 5759-1999, as amended;
•references to the “SEC” are to the U.S. Securities and Exchange Commission; and
•references to the “Merger” refer to the merger involving Anchiano Therapeutics Ltd., or Anchiano, and Chemomab Ltd., whereby a wholly owned subsidiary of Anchiano merged with and into Chemomab Ltd., with Chemomab Ltd. surviving as a wholly owned subsidiary of Anchiano. Upon consummation of the Merger on March 16, 2021, Anchiano changed its name to “Chemomab Therapeutics Ltd.” and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.

This Annual Report contains estimates, projections and other information concerning our industry and our business, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those discussed under the headings “Special Note Regarding Forward-Looking Statements” and Item 3.D. “Risk Factors” in this Annual Report.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.